Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab

समान संसाधन

• Case report: Incidental MALT lymphoma of the left adrenal gland mimicking a metastatic spread within durvalumab maintenance treatment in inoperable stage III non-small cell lung cancer
  द्वारा: Lukas Käsmann, और अन्य
  प्रकाशित: (2024-03-01)
• Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC
  द्वारा: Wang Jing, MD, और अन्य
  प्रकाशित: (2022-09-01)
• Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
  द्वारा: Johan F. Vansteenkiste, MD, PhD, और अन्य
  प्रकाशित: (2024-03-01)
• 279 Durvalumab after chemoradiotherapy for PD-L1 expressing inoperable stage III NSCLC impacts local-regional control and overall survival
  द्वारा: Lukas Kaesmann, और अन्य
  प्रकाशित: (2020-11-01)
• Prognostic significance of pretreatment PET parameters in inoperable, node-positive NSCLC patients with poor prognostic factors undergoing hypofractionated radiotherapy: a single-institution retrospective study
  द्वारा: Annemarie Barbara Zinn, और अन्य
  प्रकाशित: (2024-10-01)